Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147250 | 0.85 | CSNK2A1 (0.63) | HPGDMAPTHTTCSNK2A1AKR1C3 | |
| SCHEMBL29823118 | 0.85 | CSNK2A1 (0.63) | HPGDMAPTHTTCSNK2A1AKR1C3 | |
| SCHEMBL10621924 | 0.84 | CSNK2A1 (0.61) | HPGDMAPTHTTCSNK2A1AKR1C3 | |
| SCHEMBL2457515 | 0.83 | LIG1 (0.59) | PTGS2HPGDMAPTAKR1C3ESR1 | |
| SCHEMBL9816965 | 0.81 | CSNK2A1 (0.64) | HPGDMAPTHTTCSNK2A1AKR1C3 | |
| SCHEMBL30070764 | 0.79 | CSNK2A1 (0.62) | HPGDMAPTHTTCSNK2A1AKR1C3 | |
| SCHEMBL12333847 | 0.79 | PTGS2 (0.51) | PTGS2HTTAKR1C3ESR1 | |
| SCHEMBL2452385 | 0.78 | ELANE (0.48) | PTGS2MAPTHTT | |
| SCHEMBL8136816 | 0.78 | CSNK2A1 (0.67) | PTGS2HPGDMAPTHTTCSNK2A1 | |
| SCHEMBL14322843 | 0.77 | PTGS2 (0.57) | PTGS2HPGDMAPTESR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9176257-B2 | Conjugated aromatic compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9176257-B2 | Conjugated aromatic compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20120330052-A1 | CONJUGATED AROMATIC COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2012-12-27 | — | — | US | disclosed |
| US-20120330052-A1 | CONJUGATED AROMATIC COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2012-12-27 | — | — | US | disclosed |
| WO-2011118541-A1 | CONJUGATED AROMATIC COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330052-A1 | CONJUGATED AROMATIC COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | AHR, AXIN2, NR2E3 | PTGS2 4401/4885HPGD 3957/4885MAPT 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.